4//SEC Filing
OrbiMed Israel BioFund GP Limited Partnership 4
Accession 0001551986-20-000137
CIK 0001551986other
Filed
May 4, 8:00 PM ET
Accepted
May 5, 4:20 PM ET
Size
11.4 KB
Accession
0001551986-20-000137
Insider Transaction Report
Form 4
OrbiMed Israel GP Ltd.
Director10% Owner
Transactions
- Purchase
Series A Convertible Preferred Stock
2020-05-04+67,865→ 6,786,500 total(indirect: See Footnotes)From: 2020-05-04→ Common stock (6,786,500 underlying) - Purchase
Series A Convertible Preferred Warrant
2020-05-04+67,865→ 6,786,500 total(indirect: See Footnotes)From: 2020-05-04Exp: 2025-05-04→ Common stock (6,786,500 underlying)
OrbiMed Israel BioFund GP Limited Partnership
Director10% Owner
Transactions
- Purchase
Series A Convertible Preferred Warrant
2020-05-04+67,865→ 6,786,500 total(indirect: See Footnotes)From: 2020-05-04Exp: 2025-05-04→ Common stock (6,786,500 underlying) - Purchase
Series A Convertible Preferred Stock
2020-05-04+67,865→ 6,786,500 total(indirect: See Footnotes)From: 2020-05-04→ Common stock (6,786,500 underlying)
Footnotes (4)
- [F1]The purchase price of the Series A Convertible Preferred Stock was $58.94 per share. The Series A Preferred Stock is convertible into Common Stock upon stockholder approval on a 1-for-100 basis, with no expiration date.
- [F2]These securities are owned directly by OrbiMed Israel Partners Limited Partnership ("OIP"). OrbiMed Israel BioFund GP Limited Partnership ("OrbiMed BioFund") is the general partner of OIP, and OrbiMed Israel GP Ltd. ("OrbiMed Israel") is the general partner of OrbiMed BioFund. By virtue of such relationships, OrbiMed Israel and OrbiMed BioFund may be deemed to have voting and investment power with respect to the securities held by OIP and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the "Exchange Act").
- [F3]This report on Form 4 is jointly filed by OrbiMed Israel and OrbiMed BioFund. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, currently Nissim Darvish, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes.
- [F4]The purchase price of the warrant was included with the purchase price of the Series A Convertible Preferred Stock. The Series A Preferred Warrant is convertible into Series A Preferred Stock on a 1-for-1 basis.
Documents
Issuer
INNOVATE BIOPHARMACEUTICALS, INC.
CIK 0001551986
Entity typeother
IncorporatedIsrael
Related Parties
1- filerCIK 0001569821
Filing Metadata
- Form type
- 4
- Filed
- May 4, 8:00 PM ET
- Accepted
- May 5, 4:20 PM ET
- Size
- 11.4 KB